Bioethics and medical oversight in multi-site observational neuroimaging studies with children and adolescents: 10 years of ABCD experience Authors: Duncan B Clark, Arielle Baskin-Sommers, Susan Bookheimer, Sandra Brown, John H Evans, Dylan G Gee, Kevin M Gray, Charles Heyser, Brian Hicks, Kim LeBlanc, Leo P Sugrue Published: 2026 ABSTRACT AbstractABCD is an observational study of development and health from childhood through young adulthood. The ABCD Bioethics and Medical Oversight Advisory Group (BMO) has engaged in reviewing and advising the ABCD organization on ethical and clinical oversight issues from the initial planning of the study to the present. Anticipated ethical and clinical oversight issues included the confidentiality of participant substance use, identifying and reporting neuroanatomical anomalies, responding to imminent potential self-harm, and mandatory reporting of child maltreatment. Issues introduced by protocol updates have included return of results for metabolic syndrome and cardiovascular health risk indicators, genetic anomalies identified by DNA analyses, and a proposal to collect information from Electronic Health Records (EHR). Each site engages Site Clinicians to provide expertise and oversight in accordance with ABCD guidelines. Site-specific Emergency Management Plans and more detailed Standard Operating Procedures have been developed and implemented in several areas of concern. The ABCD Site Clinician Network has provided a forum for discussing these issues. We also discuss collaborating with the ABCD Crisis and Communications group about a data misuse incident. At present, ABCD participants are transitioning from adolescence to young adulthood, raising additional issues on consent, return of results, and procedures for addressing mental and physical health concerns. For the past ten years, we describe the implementation of the ABCD bioethics and medical oversight guidelines, the concerns and options considered, and anticipated issues arising from planned initiatives.Keywords: Adolescence, Observational research, Bioethics, Medical oversight, Consent Introduction The Adolescent Brain Cognitive Development Study (ABCD; Volkow et al., 2018) is an observational study providing knowledge on risks and resilience factors that accelerate or prevent mental and physical health problems from late childhood (age 9–10 years) through young adulthood (age 18 or older). The assessment protocols include measures of brain development, cognitive skills, mental health and physical health (see abcdstudy.org for overview). To anticipate potential bioethical and medical oversight issues, respond to concerns, and provide policy advice within the ABCD organization, the ABCD Bioethics and Medical Oversight (BMO) Advisory Group was initiated in November 2015, with the early meetings resulting in the development of an implementation strategy as described in Clark et al., (2018). We here outline the essentials of biomedical ethics pertinent to ABCD and describe the process BMO has employed in their application over the 10 years since initiation of this ongoing study. We consider privacy and safety issues in the context of consent and assent, describe our implementation approaches, and focus on key challenges in specific topic areas, including substance use, neuroanatomical anomalies, suicidal ideas and self-harm, child maltreatment and related state reporting requirements, cardiovascular risk indicators, genetic risks, and Electronic Health Records. We also consider our collaboration with the ABCD Crisis and Communication group on our response to a data misuse incident. We summarize our observations and advice on each of these topics and describe the ABCD framework for implementation. This article thus focuses on the deliberations and implementation of policies and procedures that have been critical to conducting ABCD’s observational research plan while also ethically considering privacy issues and responding to participant safety concerns. Implementation of bioethics principles The field of bioethics is quite broad. One sub-field is biomedical ethics, which encompasses clinical and human research ethics. The specific subfield of biomedical ethics has institutionalized the ethical system called principlism, where four principles are weighed and balanced. These are: (1) respect for autonomy; (2) beneficence; (3) non-maleficence; and (4) justice (Beauchamp and Childress, 1989, Gillon, 1994). As in most biomedical ethics, the BMO had to balance and weigh the applications of these principles in providing advice for ABCD. Respect for autonomy, involving the right to self-determination, is most directly applied in federal regulatory requirements for informed consent as well as assent. With minor youth (age under 18), assent applies with the caregiver providing consent. With ABCD youth transitioning to age over 18, a review of informed consent principles and issues that may arise in the change from youth assent to consent was required (e.g., Brothers et al., 2014). Respect for autonomy requires truthfulness and honesty. In some situations, adherence to beneficence and non-maleficence, promoting the wellbeing of others, may require taking some action and may, in limited circumstance, involve revealing information collected under the expectation of confidentiality, with potentially problematic consequences (Fisher, 2013). Justice, which essentially involves fairness, requires that we not involve participants with a diminished capacity to decline (e.g., incarcerated youth) or apply procedures with undue influence or deception. To provide advice on concerns that have arisen during study implementation, ABCD BMO has attended to these principles, while appreciating that there are circumstances representing conflicts among these principles, reflected in variations in stakeholder interests and viewpoints, including youth, caregivers, investigators and administrators. In the following sections, we describe and discuss examples of these points and the approaches ABCD has taken to address these dilemmas. Application of biomedical ethics principles in the context of ABCD have involved establishing procedures with consideration to various and sometimes conflicting interpretations, perspectives, and goals. Federal and state regulations, human subjects institutional review boards, and local institutional settings may provide sufficient foundational guidance in some areas, with ABCD BMO advice focusing on approaches needed to implement adherence (e.g., state mandatory reporting regulations for child maltreatment). In other areas, approaches discussed in the literature (e.g., Askari et al., 2024) and implemented in other research projects provided relevant background and structure applicable to ABCD (e.g., return of results for genetic risks). Some areas required more development of procedures (e.g., MRI incidental findings) than others (e.g., suicidal ideation and self-injury risks). ABCD BMO initially developed recommendations for guidelines (Clark et al., 2018) in an iterative process among committee members, and in collaboration with other workgroups, ABCD leadership, and scientific partners at the National Institutes of Health. In the subsequent ten years, the implementation of guidelines has been adapted as issues have been identified and clarified, and additional points have been addressed in response to added research procedures, changes in the developmental status of participants, and observations during the course of the study. The subsequent sections will describe these deliberations and the development of related procedures and other responses to concerns. Consent, assent, and decisional capacity Bioethics issues related to medical decision making in children and adolescents have been termed ‘pediatric ethics’ (Dell and Kinlaw, 2008). As implied by assigning informed consent responsibilities to caregivers, most adults are legally competent and presumed to have greater decision-making capacity than minors. As a surrogate for the minor, the caregiver is presumed to be acting with beneficence in making consent decisions. In addition, the youth provides assent, with the explanation of study procedures and expectations for youth understanding adapted as developmentally appropriate. For youth, this capability to understand study procedures and their implications and thus to provide assent is expected to improve during adolescence and, at least from a legal perspective, is presumed to reach adult status at age 18 (American Academy of Pediatrics, 1995). The concepts and procedures related to consent and assent have received some scrutiny in the literature (Morris et al., 2024). Analogous to healthcare decisional capacity (Martins et al., 2025), the ability to competently consent or assent to research involves intrinsic and extrinsic factors. Intrinsic factors include age and maturity, cognitive development, and life experiences (e.g., prior research participation). Extrinsic factors include the comprehensibility of consent and assessment materials, caregiver support and support from research team members. Research on informed consent and assent comprehension indicates that while study information can be generally presented in a comprehensible way for most youth, decisional competence substantially increases over the ABCD study ages (e.g., ages 9 through 18) and that a substantial proportion of participants may have difficulty understanding at least some study issues (Cotrim et al., 2021, Pietrzykowski and Smilowska, 2021). For circumstances in which comprehension is unclear, approaches have been developed to assess the extent to which an individual understands study procedures described in consent and assent materials (e.g., Miller et al., 1996). For such circumstances, ABCD has developed a study-specific procedure to facilitate the determination of comprehension for informed consent and assent. In addition to recommending probing for general factors (e.g., insufficient language skills; intoxication), the procedure provides specific questions that may be informative in determining comprehension. For example, questions include: “What are some of the questions we might ask you about yourself?” and “How will we protect your information?” For youth (i.e., assent), questions include: “We will keep your answers private except for a couple of reasons. Can you tell me when we might tell someone the answers you’ve told us?” and “Can you tell me about the MRI that takes pictures of the brain? I want to make sure you know what it will be like.” The intent of this framework is not to present a quiz with a pass or fail result, but to provide the team member presenting the consent or assent material with guidance to structure an inquiry to facilitate a comprehension evaluation. Developmental transitions At the time of this article preparation, ABCD participants are transitioning from minor to adulthood status (i.e., age 18 years). This change presents challenges for study policies and procedures, including but not limited to informed consent. Since many of the concerns addressed by ABCD BMO are clinical in nature (e.g., discussion of medically concerning incidental findings and referral for medical evaluation), the literature on health care transitions was informative (e.g., Paul et al., 2018). In medical systems, the transition from adolescent to adult status represents an event with medical vulnerabilities and the potential for negative health outcomes (Meyers and Irwin, 2023). To address this gap, several medical societies have proposed ‘health care transition services’ (e.g., American Academy of Pediatrics: White and Cooley, 2018). In ABCD and other research settings, youth reach ‘majority’ age at 18 years old and, at that point, provide informed consent, are the primary or exclusive source of assessed information, become the recipient of return of results and are responsible for considering safety concerns, and make decisions about clinical referral follow-up. Preparation of the youth and caregiver for this transition through discussions with the research site team may facilitate the optimal implementation of these changes. In general, adolescents are typically willing to provide valid information on sensitive topics, such as substance use or suicidal thoughts, under fully confidential conditions, while also understanding and accepting that an imminent life-threatening risk (e.g., severe suicidal ideation) may necessitate disclosure for safety purposes (Fisher, 2003). For example, youth often have confidentiality concerns about their substance use vis-à-vis their caregiver. Adherence to the conditions presented in informed consent and assent documents is required to maintain true consent. The circumstances that may be involved in the limitations of and exceptions to confidentiality need to be considered and presented to participants (Fisher, 2017). While accepting and consenting to confidentially for the youth, caregivers would also generally expect to be informed about situations in which the youth is at imminent life-threatening risk. When the youth reach adult status, they become the primary or exclusive recipient of information and recommendations and possibly providing consent for communication of findings to the caregiver. Explicit communication to the caregiver about this change in approach may be helpful to avoid misunderstandings about this process. ABCD procedures In the 10-year period since project initiation (from September 2015 to December 2025), the ABCD BMO has provided advice on and participated in the establishment and implementation of several procedures (see Table 1). The BMO advises ABCD on ethical policies and guidelines, with decisions about policies determined by the ABCD organization and the implementation of those guidelines to the sites. As described in the BMO Charter (Clark et al., 2018), the BMO members included ABCD investigators, NIH officials, and outside consultants with expertise in psychology, medicine, observational research, and ethics. Input from ABCD leadership (e.g., Coordinating Center) on topics to be addressed or perspectives to be considered has been regularly communicated. Ad hoc participants have included members of the ABCD Observational Study Monitoring Board and Expert Scientific Board, NIH officials with specific expertise, and investigators or external advisors consulting or inquiring on particular issues. Inclusion of ABCD BMO is requested on other ABCD Workgroups (e.g., Study Enhancement Review Group; Return of Results). Table 1ABCD BMO topics: 2015–2025.•ABCD Site Emergency Management Procedures•Identification of and communications with Site Clinicians•Substance use confidentiality including biospecimen findings•Neuroanatomical anomalies categorization and responses•Suicidal and self-injury risk evaluation and referral•Child maltreatment procedures and state variations•Cardiovascular risks and metabolic syndrome return of results•Genetic analysis return of results and counseling•Electronic Health Records (EHR) data collection for research•Data misuse ABCD BMO topics: 2015–2025. •ABCD Site Emergency Management Procedures ABCD Site Emergency Management Procedures •Identification of and communications with Site Clinicians Identification of and communications with Site Clinicians •Substance use confidentiality including biospecimen findings Substance use confidentiality including biospecimen findings •Neuroanatomical anomalies categorization and responses Neuroanatomical anomalies categorization and responses •Suicidal and self-injury risk evaluation and referral Suicidal and self-injury risk evaluation and referral •Child maltreatment procedures and state variations Child maltreatment procedures and state variations •Cardiovascular risks and metabolic syndrome return of results Cardiovascular risks and metabolic syndrome return of results •Genetic analysis return of results and counseling Genetic analysis return of results and counseling •Electronic Health Records (EHR) data collection for research Electronic Health Records (EHR) data collection for research •Data misuse Data misuse In a sample of 11,880 child participants, the assessments procedures identify many with at-risk characteristics. For example, across ages 9 through 15, a suicidal ideation rate of over 20% was observed (Cooper et al., 2025), indicating over 2000 youth reported suicidal thoughts. The task of appropriately responding to large numbers of such concerns has been addressed by our large network of outstanding teams at the 21 ABCD sites and the implantation of a rapid alert system when participants endorse suicidal or self-injury risks in one or more of the assessment instruments. While ethical principles have informed our policy advice, the application of formal ethical guidelines and broad clinical algorithms cannot be expected to fully identify the optimal responses for the individual cases (Fisher, 1996, 2002; Hiriscau et al., 2014). The local determination of appropriate responses led by Site Principal Investigators and Site Clinicians has resulted in a workable response network, with disclosures to caregivers and referrals to services when clinically necessary. The process of implementing procedures has involved consideration of the best interests of participants along with our obligation to conduct scientifically valid research (Fisher, 2013). Organizational integration The policies and procedures recommended by ABCD BMO are implemented and overseen by other parts of the organization. The ABCD Site Clinicians represent a distinct and critical group. While there is some overlap between investigators and Site Clinicians, in some cases Site Clinicians are not otherwise involved with ABCD. To assure that the organization communicates with and receives input from these team members, we have quarterly and as needed ABCD Site Clinicians Network meetings. Through the ABCD Coordinating Center (CC), the organization implements site monitoring, reporting, and response procedures. Monthly ABCD Council of Investigators calls are sometimes utilized to discuss or present updates. The ABCD CC conducts monthly conference calls with site staff members, training for updated or revised procedures, and an annual ‘Train-The-Trainer’ conference to assure that site team members are informed about any updates or additions to the assessments and related procedures. Site emergency management procedures In response to ABCD BMO Guidelines (Clark et al., 2018), each site has documented site-specific plans for responding to specific categories of concerns, including reports of neuroanatomical anomalies, suicidal and self-injury risks, child maltreatment, and other incidental findings. While some sections of the ABCD Site EMP documents reflect ‘boilerplate’, each site provides topic-specific Site Clinicians or other responsible individuals responsible for receipt of alerts. Also, child maltreatment and elder abuse mandatory reporting and response requirements follow state regulations and institutional policies. More detailed Standard Operating Procedure documents are focused on child maltreatment and cardiovascular risks. The Site Emergency Management Procedures documents (see example in Clark et al., 2018) have evolved over the past 10 years. For each site, the documents include Site Clinician identification, contact information and responsibilities, information on emergency contacts and resources, and brief summaries of key information points to be collected and related policies for suicidal ideas and self-harm, trauma and mandatory reporting, neuroanatomical findings, blood pressure and blood related findings, and other imminent risks. In addition, more detailed site-specific Standard Operating Procedures have been developed for trauma evaluation and reporting and blood pressure and laboratory findings (Table 2). Updates of these topics and procedures are ongoing, and current efforts are focused on adding return of results for genetic risks. In addition, each site has developed descriptions and contact information of local, state or national resources that may be pertinent for families in need of assistance (Table 3). As part of the ABCD annual site monitor visits, Site EMPs and other SOPs are reviewed and revisions are recommended as needed. Table 2Site Emergency Management Procedures sections.•Site Clinician identification, contact information and responsibilities•Brief emergency contacts and resources•For neuroradiological findings, contacts and procedures•For suicidal ideas and self-injury, key information points and policies•For child maltreatment, key information points•For blood pressure and blood findings, contacts and procedures•For other imminent risks, local contacts and procedures•Adaptations for remote visitsSupplemental Standard Operating Procedures: Child maltreatment evaluation and reporting; Blood pressure and blood laboratory findings. Site Emergency Management Procedures sections. •Site Clinician identification, contact information and responsibilities Site Clinician identification, contact information and responsibilities •Brief emergency contacts and resources Brief emergency contacts and resources •For neuroradiological findings, contacts and procedures For neuroradiological findings, contacts and procedures •For suicidal ideas and self-injury, key information points and policies For suicidal ideas and self-injury, key information points and policies •For child maltreatment, key information points For child maltreatment, key information points •For blood pressure and blood findings, contacts and procedures For blood pressure and blood findings, contacts and procedures •For other imminent risks, local contacts and procedures For other imminent risks, local contacts and procedures •Adaptations for remote visits Adaptations for remote visits Supplemental Standard Operating Procedures: Child maltreatment evaluation and reporting; Blood pressure and blood laboratory findings. Table 3Resource Guide topics.•Mental health crisis services•Emotional support helplines•Finding mental health providers•Substance use services•Legal support•Basic needs, including housing•Health insurance resources Resource Guide topics. •Mental health crisis services Mental health crisis services •Emotional support helplines Emotional support helplines •Finding mental health providers Finding mental health providers •Substance use services Substance use services •Legal support Legal support •Basic needs, including housing Basic needs, including housing •Health insurance resources Health insurance resources Site clinicians In the Site EMP, each site has identified responsible Site Clinicians in specific areas: (1) mental health (including suicidal and self-injury risks as well as child maltreatment that may require mandatory reporting); (2) neuroanatomical anomalies revealed by neuroimaging; (3) cardiovascular risks, including blood pressure and blood laboratory results; (4) genetic risks. The intent of identifying Site Clinicians in these arenas is to assure that there is a local clinician identified as willing to be responsible for responding to findings in a timely fashion. Although the responsible individuals do not necessarily have specialized expertise in the noted area, local resources have been identified in each pertinent area. To facilitate contact and to generally identify the expertise of the responsible clinicians, the Site EMP includes, for each clinician, a brief description of professional qualifications, National Provider Identifier (if applicable), and phone numbers. Secondary contacts are also identified (e.g., covering clinicians, Site Principal Investigator, and/or Project Coordinator). This detailed contact information assures that concerns that may require rapid responses can be effectively communicated to a responsible local ABCD team member. The alerts are generated either automatically from REDCap item responses (e.g., suicidal and self-injury risks) or after clinical evaluation (e.g., neuroradiology readings). Topics and challenges Substance use Substance use is extensively evaluated in the ABCD assessment protocol. At baseline (i.e., age 9–10), few youth reported engaging in substance use (Lisdahl et al., 2021). As expected, subsequent assessments show self-reported increases in substance use rates (e.g., ages 13–14: past year: alcohol use: 10%; cannabis use: 3%: Jones et al., 2026) with higher rates expected of these and other substances at older ages. Additional information on substance use characteristics of the ABCD sample has been reported (Sullivan et al., 2022; Wade et al., 2023). The caregiver may have limited awareness of youth substance use transitions (Berge et al., 2015). Also, discordance between youth report and biospecimen results has been noted in other studies (Delaney-Black et al., 2010). ABCD consent and assent conditions indicate that youth self-report and biospecimen substance use information will not be shared with the caregiver, potentially involving tension among the bioethics principles of respect for autonomy (i.e., a youth’s wishes; consent and assent conditions), and beneficence (i.e., possible benefits of breaking confidentiality). Youth and caregivers generally agree that such exigent circumstances where the youth is in immediate jeopardy constitute an appropriate confidentiality exception or limitation (Fisher, 2013). ABCD BMO has advised and ABCD Coordinating Center has supported and encouraged that sites have naloxone (i.e., Narcan) available and that ABCD team members be trained in its use. This exception for exigent circumstances indicating ‘imminent life-threatening risk’ is an application of the non-maleficence bioethics principle. We note that the general confidentiality exception for exigent circumstances indicating ‘imminent life-threatening risk’ is pertinent across all topic areas. The ABCD BMO position is that the determination of ‘imminent life-threatening risk’ and related responses are optimally made by Site Clinicians based on the totality of circumstances as presented in an individual instance. In each case, there are anticipated and unanticipated clinical circumstances that need to be considered and that may be interpreted as surpassing this threshold. Therefore, the ABCD BMO has decided not to attempt to create or identify the broad array of clinical definitions and response algorithms that would be needed for this purpose. The review of the experiences of other research projects may provide informative background. For example, HEALthy Brain and Child Development (HBCD: Kingsley et al., 2024) is a large study on child development with data collection beginning at birth and focused on early childhood. While the developmental focus is earlier than ABCD, the organization is analogous and some HBCD deliberations may be informative to ABCD. HBCD has considered an instance where a participant who did not report a history of fentanyl use had a biospecimen positive for fentanyl. HBCD deliberations considered that an individual may have been unknowingly exposed to fentanyl (e.g., by consuming an adulterated substance). In the context of a prior commitment to participants that biospecimen results would not be returned to them, the possibility of linking biospecimen data back to individual participants was nevertheless considered for safety reasons. Factors in their decision included that biospecimen processing and analyses are batched and therefore a return of the results may occur a long period of time after specimen collection. While one might imagine that an individual receiving this information might choose to reduce their risk, this circumstance does not meet the criterion of an ‘imminent life-threatening risk’, given the inherent delay in returning the processed results. HBCD also noted that returning these results could introduce legal risk, such as an interpretation that this information might need to be reported to the state child welfare system. Furthermore, HBCD noted that contradicting the consent conditions could diminish participant trust and compromise subsequent self-reported substance use. HBCD elected to provide aggregate feedback to participants with harm reduction resources to reduce fentanyl exposure risk. While the pertinent HBCD participants (e.g., an adult parent) are quite different than pertinent ABCD participants (e.g., an adolescent minor), the features to be considered have parallels with ABCD. In ABCD, caregivers are explicitly consented with the understanding that hair toxicology results (see Wade et al., 2023 for a description) from youth will not be provided to them and youth are assured that substance use findings are kept confidential. ABCD hair specimen results become available months or, in some cases, even years after specimen collection, thereby not meeting the ‘imminent’ feature of the exception criterion of ‘imminent life-threatening risk.’ In addition, these results are not available for all participants. For these reasons and among youth (<18 years), the ABCD BMO advised keeping hair toxicology results confidential. To provide information on overdose risks to participants, ABCD is providing all participants with information on inadvertent fentanyl exposure through adulterated illicit drugs or counterfeit pills and the related serious hazards, and through an infographic that is also available through our website (abcdstudy.org/youth-resources/youth-resources-prevention). The ABCD Coordinating Center has held training sessions and provided related materials for investigators and staff and a national substance use webinar (available at abcdstudy.org) was held which included a focus on fentanyl. Since substance use is a central risk and outcome for the ABCD study, the validity of youth reports on their substance use is critical to the scientific value of the program. At the same time, youth participants may provide information that would indicate the potential for ABCD team members to intervene by ‘breaking’ confidentiality. Adhering to the principle of ‘respect for autonomy,’ such actions would require that the information be collected with an understanding by youth and caregivers that substance use youth assessments and analyses from biospecimens would be provided to the caregiver. This condition would likely lead to invalid reports or declining biospecimen collection, diminishing the scientific value of ABCD. Rather, we elected to clearly communicate from the outset that such results would not be communicated. Instead, each caregiver and youth are provided with resource options, including local addiction assessment and treatment centers, and access to Site Clinicians for discussions about concerns. The consent and assent documents also acknowledge that exigent circumstances involving imminent life-threatening incidents may supersede confidentiality concerns. This approach has been the subject of extensive and ongoing consideration and discussion that will undoubtedly continue as the participants transition to young adulthood. ABCD is currently reviewing options for providing hair toxicology results to consenting participants over 18 years old. Neuroanatomical anomalies At the outset, and based on prior studies (e.g., Borgelt et al., 2013; Cole et al., 2015; Illes et al., 2006; Sullivan et al., 2017), ABCD recognized that neuroanatomical anomalies would occur as incidental findings in a proportion of youth, which could represent a substantial number when considering the scale of ABCD. To ensure participant safety, T1 and T2 structural sequences from all MRIs obtained in the study were centrally reviewed by neuroradiologists and screened for structural anomalies. The rationale for our approach and the system developed for neuroradiological review and results of review of the baseline ABCD imaging have been described (Clark et al., 2018, Li et al., 2021). Briefly, a neuroradiologist reviews each structural MRI (current and past) and generates an individualized report for each scan using a categorical scoring system (adapted from Shoemaker et al., 2011, Shoemaker et al., 2016): Category 1, no abnormal findings; Category 2, normal anatomic variant or common incidental finding unlikely to be of clinical significance in a healthy individual, no referral necessary; Category 3, consider referral; and Category 4, consider immediate referral. Table 4 shows the distributions of imaging scores across the four categories for ABCD participants with interpretable imaging at available timepoints. For the baseline imaging, the most common findings indicating a need to consider clinical referral were white matter lesions (n = 188), heterotopias or dysplasias (n = 117), tonsillar ectopia or Chiari 1 malformation (n = 71), and possible brain tumors (n = 34). These rates are generally consistent with reports from other studies (Gur et al., 2013, Seki et al., 2010; Sullivan et al., 2017). While most incidental findings were evident at baseline, subsequent MRIs sometimes revealed new or progressive changes. Table 4Distribution of Category 1–4: Findings in the participants in the ABCD cohort with interpretable imaging at each of the 4 imaging timepoints included in ABCD Data Release 7.0.Category*Baseline2-year FU4-year FU6-year FU19215 (78.9%)5647 (69.8%)4342 (68.2%)5074 (66.4%)22014 (17.2%)2072 (25.6%)1687 (26.5%)2152 (28.2%)3429 (3.67%)369 (4.56%)331 (5.20%)413 (5.40%)420 (0.23%)5 (0.04%)3 (0.05%)5 (0.07%)Totals11678809363637644*Category definitions: 1: No abnormal findings; 2: Normal anatomical variant of no clinical significance; 3: Consider clinical referral; 4: Consider immediate clinical referral; FU: follow-up. Distribution of Category 1–4: Findings in the participants in the ABCD cohort with interpretable imaging at each of the 4 imaging timepoints included in ABCD Data Release 7.0. *Category definitions: 1: No abnormal findings; 2: Normal anatomical variant of no clinical significance; 3: Consider clinical referral; 4: Consider immediate clinical referral; FU: follow-up. Since the ABCD MRI data collection and review procedures are not intended as clinical evaluations, direct communication of imaging reports to caregivers was not thought to be appropriate. Instead, the ABCD BMO decided upon the following process: Category 2 findings were not communicated due to concerns about creating unwarranted concern and unnecessary medical evaluations, which might also result in expenses for the family (Royal and Peterson, 2008) for findings unlikely to be clinically significant in an otherwise healthy individual. Category 3 and 4 findings were communicated to a Site Clinician for consideration of non-urgent (Category 3) or immediate referral (Category 4). For Category 3 findings, some findings are ambiguous, and consideration needs to be given as to whether communication to the caregiver is appropriate. When communication is deemed necessary, the description of results may require some level of expertise or at least expert guidance. Sites vary on the availability of neuroradiology expertise, and the ABCD neuroradiology team is available for consultation. While referral to a primary care provider might be a necessary first step (e.g., for correlation with medical history or symptoms; coordination of care), some Category 4 findings may warrant direct referral to a neurologist or neurosurgeon. From an organizational standpoint, accounting for the receipt of and response to this information was deemed necessary. Therefore, the Site Clinician receives an email message with the neuroradiology report and is required to provides an initial “acknowledgement” response on receipt of the email. After evaluating the results, the responsible site clinician provides information about their response (e.g., ‘discussed with family,’ ‘referral recommended,’ ‘clinical follow-up confirmed’). Follow-up with the Site Clinician is initiated if these steps are not completed. This communication process and related logistics have been a subject of ongoing discussions and refinement. The development and implementation of this process for ABCD has added to a consensus in the field (e.g., cited in Rowley et al., 2023) that routine neuroradiologist review of research MRIs is needed to provide for participant safety (i.e., beneficence). The time frames for the communication of results vary. In some instances, neuroanatomical anomalies may be identified at the time of the scan and a response may be initiated by the site. All ABCD MRIs are centrally reviewed by a neuroradiologist. After the participant completes the MRI at the site, the site is expected to send images to the ABCD Data Analysis, Informatics, and Resource Center (DAIRC) within 24 h. The DAIRC then provides the images to the neuroradiology group for review within 14 business days. Scores of 3 or 4 are communicated to the site’s designated recipients, including the Site Clinician responsible for neuroanatomical anomalies. The site recipients are then expected to acknowledge receipt within 48 h. For Category 3, the responsible Site Clinician is expected to contact the parent and/or participant and resolve the alert through communication DAIRC within 14 days. For Category 4, the Site Clinician is expected to communicate with the parent and/or participant as soon as possible and to reach a resolution regarding communication and referral within 72 h. Thus, while resolution for Category 4 reports is expected as soon as possible, for Category 3 reports, which represent the majority of reported observations, the process from MRI collection to resolution may take up to four weeks. While communication about neuroanatomical anomalies has not been controversial, challenges have nevertheless emerged. The ABCD MRI protocol was not intended to provide clinical findings and identified anomalies may have ambiguous implications. In some instances, Site Clinicians may be reluctant to communicate the neuroradiologist report to caregivers without further guidance, since the findings typically require an explanation of possibilities, which may range from ‘normal variant’ to worrisome neurological disorders. Communicating ambiguous MRI findings may not be entirely benign, even if ultimately found to be a ‘normal variant,’ due to precepting caregiver worry, logistical challenges in pursuing further evaluation, and related expenses. Even pathological findings that lead to successful preventive interventions (e.g., neurosurgery) may raise doubts as to whether the intervention was necessary. Despite these concerns, the ABCD procedures for identifying and responding to neuroanatomical anomalies have been found reasonably robust, with primarily logistic adjustments to facilitate communication, provide for Site Clinician consultation with a neuroradiologist, and improve process monitoring. Suicidal and self-injury risks The ABCD assessment protocol includes the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS: Kaufman and Scheweder, 2004) items on suicidal and self-injury risks. Baseline (age 9–10: n = 11814) findings show lifetime prevalences as follows (DeVille et al., 2020): passive suicidal ideation: 6.4%; nonspecific active suicidal ideation: 4.4%; active ideation with method, intent or plan: 2.4%; suicide attempts: 1.3%; non-suicidal self-injury: 9.1%. In an analysis of pooled data through the third ABCD follow-up assessment (mean age 12.9 years: Thompson et al., 2022), overall rates were 21.8% (1940/8895) for suicidal ideation and 4.2% for suicide attempt (373/8895). These ABCD prevalence rates are similar to those in other cohorts (Cooper et al., 2025). ABCD’s approach to handling the assessment of suicidal and self-injury risks among youth has been informed by ethical considerations, such as consideration of both safety and confidentiality. To ensure that youth and caregivers understand limits on confidentiality, informed consent and assent explicitly address how limits on confidentiality include imminent risk of harm to oneself or others. Given the scientific value of multiple informants, both caregivers and youth themselves respond to questions about youth suicidal and self-injury risks. As planned (Clark et al., 2018), an affirmative answer to suicidal and self-injury risk assessment items in REDCap triggers an automated email alert to the ABCD Site Clinician via email and text. The Site Clinician is required to respond to the message with an acknowledgement. Each Site EMP includes a brief guide to the collection of pertinent information. As implied by the above numbers (e.g., about 2000 participants with these alerts), there is a substantial effort needed to respond, collect additional information, and provide a referral or imminent management if needed. Affirmative responses may be for instances distant from the time of assessment, may have already been the focus of a clinical assessment, or may have otherwise been clearly resolved. Other responses, on inquiry, may be determined to be of minimal clinical significance. Some youth are receiving ongoing behavioral treatment, such that a referral would be superfluous. Furthermore, each site provides every youth and caregiver with the above noted resource guide listing options for obtaining additional referral information or emergent evaluation. In many instances, additional information may be collected by the assessment team member engaged with the participants and reviewed with the Site Clinician to decide whether additional information is needed to inform decision making and whether informing the caregiver is necessary. In the rare instances, the ABCD assessment and supplemental inquiry have revealed an imminent life-threatening emergency requiring an immediate response to safeguard the participant. Each site has locally relevant contingencies for these circumstances. Thus, while there has been a large volume of these alerts, sites have developed reasonably efficient approaches to their resolution in most cases. While these responses to assure participant safety have been relatively uncontroversial in ABCD implementation, we acknowledge that this limit to confidentiality may to some degree have unintended consequences. Particularly in subsequent visits after youth participants have reported suicidal ideas and subsequently participated in further interviews or referral, some adolescents may perceive these efforts as burdensome, unnecessary, or a breach of confidentiality and may then be less likely to disclose suicidal ideas (Lothen-Kline et al., 2003). While ethically sound, research validity on this topic may be hampered. Our observational design does not include a method for determining whether subsequent reporting may be influenced, although this could be a topic for additional research. Child maltreatment, PTSD and state reporting requirements In ABCD, the youth history of potentially traumatic events that may require clinical follow-up, including child maltreatment, are primarily assessed with the trauma interview in the PTSD section of the Kiddie Schedule for Affective Disorders and Schizophrenia – Present and Lifetime Version for DSM−5 (KSADS: Kaufmann and Schweder, 2004; Townsend et al., 2020). For baseline through six-year follow-up, this information was collected from the caregiver. While trauma-related items were limited to caregiver-report in the early years of the study, beginning at age 16, it was deemed developmentally appropriate and important for scientific validity to directly ask youth about exposure, given that caregivers may be increasingly less aware of adolescents’ experiences and that caregiver and youth reports of trauma exposure can be quite discrepant in adolescence (Kuo et al., 2000; Stover et al., 2010; Skar et al., 2021). Therefore, starting with the six-year follow-up and for subsequent visits, youth ages 16 and older also respond to these items. For youth at age 18–19 (i.e., nine-year follow-up), we have added the Childhood Trauma Questionnaire (Spinhoven et al., 2014). At ABCD age 9–10, the types and rates of potentially traumatic events determined by the KSADS PTSD module that may need further inquiry to determine whether referral or mandatory reporting are needed have been reported as follows (Thompson et al., 2022): witnessed domestic violence (8.1%); sexual trauma (2.0%); physical abuse, assault or threats to kill (1.8%). Endorsement of these items prompts an alert to the Site Clinician for follow-up (a.k.a. KSADS PTSD alert), including potential clinical referral as well as decisions about whether state regulations require mandatory reporting for potential child and family services investigation. While many adolescents experience potentially traumatic events, the lifetime prevalence of posttraumatic stress disorder (PTSD) among adolescents is about 5% (McLaughlin et al., 2013), with lifetime rates of potentially traumatic events ranging from witnessing the unexpected death of a loved one (29% of the sample) to being the victim of physical abuse by a caregiver (1.7%). Traumatic events that involve interpersonal violence are more likely to elicit persistent mental health consequences, including PTSD (e.g., Clark et al., 2010). At baseline, based on caregiver report, lifetime PTSD has been reported present in 2.2% of ABCD participants (Levin and Liu, 2024). ABCD inquiry procedures for child maltreatment include program-wide as well as site-specific features. The Site EMP includes abbreviated key information on these procedures that may be emergently needed, including: the pertinent Site Clinician; a statement on confidentiality limitations that may need to be provided to the caregiver and youth; information to be collected after receipt of an alert (triggered through REDCap through KSADS or CTQ items); contact information for local or state mandatory reporting instructions and related resources. To supplement these key points, ABCD also has developed and requires each site to have available a site-specific ABCD PTSD SOP for KSADS and CTQ. This document includes more detailed guidelines on trauma-related assessment and follow-up, including points on interviewing approaches, scripted open-ended questions that may be helpful in collecting additional information, specific information that may be needed for both clinical and reporting purposes, a determination about whether a prior report about an incident has been filed, and suggestions for assessing and facilitating youth or caregiver safety. Pertinent details on state regulations, such as child maltreatment definitions and links to state regulations or training resources, may also be included. It is important to note that sexual relations between minors can also require reporting, with specific regulations varying across states. The ABCD consortium, with input from BMO, has faced a range of ethical considerations related to child maltreatment assessment and mandated reporting over the course of the study. An important early decision concerned whether to collect data on trauma exposure, particularly maltreatment. Prior to study initiation, there was some concern expressed about the trauma assessment and attendant likelihood that ‘mandatory reporting’ would be required in some instances. In recognition of the significant role of trauma in shaping development, trauma exposure items, including maltreatment, were included in the protocol with planning for sensitive and appropriate handling of potential disclosures. To ensure transparency and that participants understood the implications of their responses, informed consent and assent explicitly describe that child maltreatment reports are governed by mandated reporting regulations and are thus not held in confidence. The consortium also deliberated about whether trauma exposure should be assessed solely via caregiver report or directly with youth. While trauma-related items were limited to caregiver-report in the early years of the study, beginning at age 16, it was deemed developmentally appropriate and important for scientific validity to directly ask youth about exposure, given that caregivers may be increasingly less aware of adolescents’ experiences and that caregiver and youth reports of trauma exposure may be discrepant, particularly in later adolescence. Mandated reporting procedures vary across states and as a function of participants’ age. With regard to youth age, ABCD sites modified their SOPs for participants transitioning to 18 years old. While no longer considered minors for purposes of mandated reporting, some endorsements of trauma exposure may necessitate mandated reporting. For example, disclosures may indicate ongoing risk to minors, such as younger siblings. Thus, ABCD procedures continue to entail research staff following up on potentially reportable endorsements with specific queries to facilitate Site Clinicians’ determinations about the applicability of mandated reporting regulations. While some states do not require reporting when an 18-year-old discloses abuse that occurred in the past and there is no reasonable suspicion of current risk to a minor, others do have specific reporting requirements. For example, Minnesota law requires mandated reporters to report past abuse of a minor that occurred within the last three years, even if the victim is over age 18 at the time of disclosure. To complement state-required training for mandated reporters, ABCD developed research-specific training on ABCD investigators and staff responses to child maltreatment. Regardless of whether a disclosure met criteria for mandated reporting, all participants who endorse trauma exposure are provided with mental health resources. Procedurally, another consideration involved procedures to follow up with participants in order to gather sufficient information to assess whether a disclosure warranted mandated reporting. While prioritizing youth safety and compliance with legal reporting requirements are paramount, follow-up procedures need to be implemented within the context of a lengthy research protocol, with attention to minimizing participant burden and respecting privacy where feasible. To balance these considerations, research staff are trained to obtain only key information (e.g., when event occurred, who was involved in event, whether event was previously reported to authorities). The mandatory reporting procedures are dictated by state regulations. Among the initial concerns about assessing trauma exposure was that a significant proportion of caregivers may be subjected to inappropriate or unhelpful investigations. While the responses of families to reporting to governmental authorities has not been a subject of ABCD research, significant disruption does not seem to have occurred. Valuable scientific data have been collected in the arena of traumatic experiences, increasingly recognized as important in understanding adolescent mental and physical health. In some instances, helpful interventions may have resulted. Cardiovascular Health Risks Cardiovascular health risks (CVH), including modifiable health behaviors (e.g., sleep, physical activity) and indicators of metabolic syndrome (e.g., Life’s Essential 8: Lloyd-Jones et al., 2022) have been extensively studied in adults, and found associated with mental and physical health characteristics. The relationship of CVH to healthy adolescent development has been less well characterized. Consequently, in 2020, ABCD supplemented the CVH assessment to include blood pressure and blood-related indicators, including A1C, total cholesterol and high-density lipoprotein. For ages 11–12, ABCD results to date (De Moraes et al., 2024) indicate that positive CVH indicators are associated with better executive cognitive functioning and structural brain characteristics, including greater mean cortical thickness. ABCD provides these added CVH indicators directly to all caregivers and youth in a format that includes numerical results and explanatory information. The indicators included in caregiver and youth communications are: blood pressure; high-density lipoprotein (HDL) cholesterol; total cholesterol; A1C. This ‘return of results’ decision, which includes providing normative findings, was developed with ABCD BMO input. While many ABCD results are not returned to caregivers and youth, the report of CVH indicators that might not be typically measured at home, including blood pressure, was thought to be potentially valuable to the participants, possibly actionable, and unlikely to be associated with youth confidentiality concerns. In rare instances, blood pressure observations could indicate an imminent life-threatening risk (e.g., Hypertensive Emergency: BP > 180/120) and results would be reported to the participant and/or caregiver as directed by the Site Clinician. (For ABCD, we are not aware of any such results to date.) Other blood-related indicators are screened by an ABCD Coordinating Center enlisted physician and communicated to the Site Clinician for further follow-up as indicated. The recommendations of content experts were solicited and published guidelines from authoritative organizations (e.g., American Academy of Pediatrics: Flynn et al., 2017) were reviewed by ABCD BMO and other workgroups. The addition of CVH indicators was thus accompanied by procedures that identify ‘out of range’ or abnormal findings that require alerting Site Clinician and consideration of clinical referrals as well as routine return of results to caregivers and youth participants. The extent to which ABCD provides return of results to caregivers and youth when findings are not a cause for concern has been a topic of ongoing discussion. For CVH findings that are ‘within normal limits,’ ABCD has, with BMO input, adopted a procedure to directly provide each caregiver and youth these indicators with educational text on their implications. For CVH, the issues to be considered are qualitatively different than for substance use, suicidal and self-injury risks or child maltreatment. While blood pressure may be readily available to most participants, the individual value along a definition and the interpretative information provided may be useful to participants. HDL and A1C might not be otherwise available, and providing these values with explanations and interpretations provides testing recommended by the American Academy of Pediatrics with educational information. By providing this information, ABCD intends to provide a valuable service to participants and hopes that this feedback encourages continued engagement. There are ongoing discussions about expanding return of results in other areas. Genetic analyses and related risks ABCD participants provide saliva and blood DNA samples for genomic analyses. In ABCD to date, many participants have been genotyped, providing data which has been primarily utilized to generate polygenic risk scores. ABCD polygenic risk scores have been utilized in many ABCD publications, and the potential and limitations of this approach have been discussed and debated (e.g., Shar, 2022). In 2020, Whole Genome Sequencing (WGS) was initiated in ABCD, which will greatly expand the value of this scientific resource. WGS also provides the opportunity to identify potentially medically actionable pathogenic genetic risk variants. In collaboration with the ABCD Genetics and Return of Results Workgroups, the ABCD BMO reviewed the bioethical and medical oversight issues that these results invoke. The best practices developed by American College of Medical Genetics and Genomics (ACMG: Miller et al., 2021) and complementary options by other groups were considered. Adopting ACMG guidelines, the ABCD Genetics Workgroup proposal was to provide participants with pre-consent educational materials which include information on genetics and how genes affect our health, the ACMG secondary findings list and the sorts of conditions involved, and the pros and cons of receiving these results (ACMG Guidelines: Miller et al., 2021). The process includes steps to obtain informed consent (Henderson et al., 2014) and provisions for genetic counseling. Participants may opt in or out of receiving this information. The ACMG list includes genetic disorder risks where the associated condition may remain undiagnosed and medical interventions are available to improve health outcomes. The prevalence of such findings in the population is approximately 3–4% with some variants associated with earlier deaths from actionable conditions (Jensson et al., 2023). This approach now has a 10-year history and has been adopted by several contemporary research projects (e.g., All of Us: Venner et al., 2022). These procedures and related research involving ABCD, All of Us and other projects will likely inform the development of genetic screening through health systems (Plon and Jarvik, 2023). The ABCD procedures for providing genetic return of results have been developed. ABCD will follow best practices and examples set by other large observational cohort studies, such as the All of Us Research Program (Venner et al., 2022). “Negative” results – cases for which we do not detect any variants from the ACMG Guidelines v3.2 list (Miller et al., 2021) – will be returned with a brief explanation and important caveats about what this does and doesn’t mean for disease risk for the future. For “positive” results, the Site Clinician or other local point of contact will reach out to schedule a ‘warm hand-off’ session. The Site Clinician will not know or disclose the actual results but will explain the process for getting the clinical confirmatory test done and will obtain the participant’s consent to proceed. The participant may request to speak to a genetic counselor at any point in time, including before their initial consent. If the confirmatory test is positive, the third-party testing and genetic counseling service will send results to the participant and reach out to schedule a genetic counseling session to discuss the implications of their results. The participant may include additional family members in this process. This process, as well as background on the information that will be reported and participant responses and concerns may arise, are all discussed in the educational materials that are required to be provided during the initial consent. Research utilizing DNA analyses is rapidly advancing and the scientific value of genetic data is being increasingly realized (e.g., Grotzinger et al., 2026). Whole Genome Sequencing analysis potentially represents a future benefit to participants. While pertinent for only a small proportion of the ABCD sample, the potential participant benefits of identifying and successfully responding to a genetic risk could far exceed other benefits that might be gained from research participation. As with other return of results areas, and perhaps outside the scope of ABCD, information about participant communication, genetic counseling, and follow-through with related recommendations would be informative not only for research programs but also for evaluation of the possibility that such genetic screening may be worthwhile in clinical practice. Future directions: electronic health records Electronic health records (EHR) represent a potentially valuable source of health information with low participant burden. The integration of EHR with research data has been extensively explored in the All of Us Research Program. In general, participants are willing to share EHR in the research context. In All of Us, for example, only 2.3% declined access to EHR, with younger age, female sex, and higher education, and not race and ethnicity, related to a decision to decline EHR access (Joseph et al., 2022). While a valuable source of information in many arenas, EHR content deficits or information structures pertaining to some topics (e.g., genetic testing) can make interpretation problematic and lead to recommendations for altering EHR data structures to be more amenable to research (e.g., Underhill et al., 2025). Comparing EHR and research data, All of Us analyses have identified areas with concordant (e.g., cancer) or discordant (infectious disease) information (Sulieman et al., 2022). Some EHR research has shown notable deficits in mental health arenas, including diagnoses, visits and hospitalizations, specialty care, and medications (Madden et al., 2016). With the methods, benefits and limitations of EHR data identified in other projects, ABCD is pilot testing the collection of EHR, with consent and data collection initiation coinciding with the participant transition to adult status (i.e., age 18 years). EHR would primarily be utilized to add contributory health information to ABCD outcomes. In collaboration with other ABCD workgroups, ABCD BMO has considered bioethical and medical oversight issues with EHR data collection and utilization. The research rationale, proposed methods, issues regarding engaging and educating participants on the informed consent and data collection procedures, privacy and data security concerns, data quality and interpretation, and the balances of potentially competing ethical principles have been discussed. The initiation of this consent at the adolescent to adult transition age raises issues related to the extent of appropriate caregiver engagement in the context of youth ‘majority’ age consent. Caregiver input may often be needed due to variations in youth awareness of and ability to provide necessary information on prior pediatric practitioners and associated medical organizations. While still under consideration and review, at this time we expect that the EHR consent will be for all available records, including those prior to study participation. For the inclusion of EHR data in future ABCD protocols, pilot testing is underway. Based on prior studies, a high rate of participation is likely. There may be anticipated challenges in asking young adults to provide information about their medical history needed to obtain records. For EHR obtained and producing data, comparisons of medical records with ABCD’s research protocol-derived assessments will be informative both for identifying areas where ABCD may need additions and for evaluating clinically relevant characteristics where EHR documentation needs to be improved. Ethical concerns about data misuse As required by NIH, ABCD provides a cumulative de-identified data set to the NIH Brain Development Cohort (NBDC) Data Hub, along with guidelines and resources to facilitate ethical use of data. NBDC manages applications for data access and data management procedures. In addition to demonstrating qualifications and stating the intended data use, the recipient is required to attest to adherence to data security procedures and ethical standards for data use and interpretation. To further facilitate accurate interpretation of online and published findings, the ABCD has both a Community Engagement and Dissemination Committee and a Crisis and Communication Team. ABCD investigators have published articles both describing best practices for ethical data use, as well as multiple editorials encouraging adherence to these standards (e.g., Brown et al., 2024; Gonzalez et al., 2025). The Open Science model of ABCD has produced accelerated scientific discovery with few incidents of data misuse. Nevertheless, ethical data use guidance, data user assurances, and technical safeguards to data access cannot fully protect against analytic and interpretive misuse. ABCD has faced two types of data misuse reflecting ethical challenges associated with the open science model: unauthorized or inappropriate access to data and unethical reporting of misleading results. A data misuse challenge involving ABCD was the subject of a 2026 New York Times (NYT) article which reported that the ABCD Study(R) did not keep their data safe, which led to unauthorized use by individuals seeking to argue for the innate intellectual superiority of White people. The article presented misleading statements about ABCD, implied that related publications were based on ABCD data and misrepresented data access standards of the NIH open science data efforts. The NYT article accurately reported that an investigator provided misleading information to the NIH data repository system about his identity and planned use of the data to obtain access to the ABCD data set. However, a reference to 16 articles that reportedly used ABCD data was inaccurate as these articles did not, in fact, use ABCD data. This investigator, however, did share data in violation with his federal agreement with an unauthorized person who subsequently posted materials on social media and limited-circulation or non-mainstream publication venues. NIH has barred this investigator from accessing ABCD and other open science data. This purposeful behavior was in violation of NIH policies, and the explicit ethical standards of numerous professional organizations as well as the publication standards for research institutions. Such public misinformation is an affront to the participants in the study and damages trust in science, which inhibits the willingness of the public to engage in scientific studies. Minoritized groups, who have experienced the consequences of unethical scientific activities in the past, are disproportionately impacted. ABCD addressed these issues in several ways. To mitigate the adverse consequences of the NYT article for participants: 1) all youth and parent participants were individually informed via text and email of a letter for them and Frequently Asked Questions to succinctly address questions and concerns from the article; 2) an announcement was posted on the ABCD website of our concerns linking families directly to the letter and FAQs; 3) a monitoring system was established to track questions from the cohort and how they were individually addressed by site Principal Investigators; 4) communication materials were prepared for staff working directly with participants and investigators who may be asked to communicate with the press; 5) withdrawals were tracked by site; and 6) social media statements were developed and posted. Administratively, the Institutional Review Board (IRB) responsible for managing all ABCD sites was informed of the article and the consortium’s responses. Further, the situation was reviewed internally (Coordinating Center leadership, BMO; Council of investigator Zoom meetings) and externally (NIH leadership meeting; Observational Safety Monitoring Board; External Scientific Board; National Liaison Board). Finally, ABCD sought to inform the public and stakeholders via a statement regarding open science, which included reference to the NYT article and data misuse risk posted on the ABCD website, and was sent to 22 national professional organizations and also shared with PIs for distribution to community groups they wished to inform. While these efforts were helpful and reflect the depth of concern of the ABCD consortium for families who contributed to our research for almost ten years and constituted the basis for the more than 1900 peer-reviewed publications of ABCD, they cannot fully compensate for the duress experienced by some of the participating families. This was particularly evident for families from minoritized groups who may have experienced past data misuse or research-related distress in prior studies related to the community with whom they identify. By way of long-term follow-up, ABCD is launching an advisory group to further guide sensitive decisions about data misuse and has plans to engage further with participants to understand their perspectives and wishes regarding when and how to keep them informed of data breaches and misuse of data. The NIH also continues to act to further ensure that de-identified data access is restricted to qualified researchers with institutional verification who must submit proposals, agree to strict data use certifications, and undergo training in responsible data handling and ethical use of data. Access to ABCD data is administered through NIH data repositories and governed by federal data use agreements. Enhanced technical safeguards to data access protect but cannot fully prevent analytic and interpretive misuse. While welcome, these efforts will not prevent all data misuse. Similar concerns have arisen and have been debated for decades (e.g., Scarr-Salapetek, 1971). Scientists, journal editors, reviewers, and the public all share responsibility for how research is shared and understood. This heightened responsibility to uphold ethical standards is particularly salient in findings reported in social media where standards for accountability are mixed at best. Without critical scrutiny of research findings on everyone’s part, data can be misused in ways that reinforce biases, ignore influential factors, and operate to increase health disparities for those most impacted by the reports. Conclusion The bioethical principles that are used in research on human subjects are rarely sufficient for informing categorical objective decisions and related actions. As in all principlist bioethics, we have had to weigh, balance and interpret the connection of the issues to the principles. For example, the broad developmental window, from age 9 through 19 during the 10-year study period, has presented challenges for adapting policies and procedures which, along with protocol additions, has required continued consideration to balance the respect for autonomy and confidentiality concerns with responses that may be optimal for improving the health of youth participants. This is all while keeping in mind the capabilities and limitations of the investigative teams, and awareness of the possibility of biasing assessment responses in the context of validly conducting an observational study. While the structure of consent and assent changes when the youth participants reach age 18, this landmark typically does not fully coincide with categorical changes in the youth-caregiver relationship. Many youth may continue to rely on the caregiver for logistic support (e.g., scheduling, transportation), information (e.g., medication details; medical practitioner and institution history for EHR), and decision-making guidance not directed acknowledged by this change in responsibilities. Shifting consent from caregiver to youth may prompt reconsideration of the participant’s protocol understanding and competence. The participant’s response to recommendations for clinical follow-up may necessitate caregiver assistance. Should ABCD continue to conduct assessments with these participants, youth will shift into adulthood and further adaptations will be necessary. The ABCD site team will need to navigate these issues keeping in mind the youth’s right to self-determination (i.e., respect for autonomy), transparent discussions on caregiver involvement, promotion of youth well-being (beneficence) and preventing harm (non-maleficence). The organizational structure for identifying and responding to potential safety issues has contributed to providing resource referrals where needed, assuring all involved, including caregivers, youth, ABCD team members and administrators, that a carefully considered procedure with monitoring has been implemented. The explicit development and updates of Site Emergency Management Procedures and other SOPs involve each of the site teams in developing and implementing these procedures. The ABCD Site Clinicians have been a key factor in engaging experts in making considered decisions and taking responsibility for following through on identified safety issues. The ABCD Site Clinicians Network has provided a forum for communication and discussions about these critical issues. The involvement of the entire ABCD organization in working through the issues described here, including internal workgroups and external committees, has been an important feature of the success of the process. In summary, while bioethics principles provide an informative conceptual framework that we have referenced throughout our deliberations, most of our attention has been focused on specific structures and details about implementing procedures in keeping with these global concepts. In the past 10 years, ABCD BMO has provided advice on a broad range of topics. The ongoing engagement of the entire ABCD organization through investigator meetings, workgroups, staff meetings and training, site monitor visits, site Community Liaison Board input, and leadership interactions across these groups has been essential to the success of the ABCD approach. Each site developing, sharing and implementing the EMP and related SOPs has engaged a broad representation of leadership, investigators and staff in discussions about these safety issues and procedures. The EMP identifies Site Clinicians as the recipients for alerts, individuals who are typically called upon to respond to local challenges when needed. Each site also maintains lists of resources that may be pertinent for many youths and their caregivers. Taken together, this structure provides a sufficient and scalable approach to facilitate each site taking necessary steps to have clear and readily accessed safety procedures and resources in place that reflect respect for autonomy, truthfulness and beneficence. This intent and the structure and procedures developed by ABCD may be pertinent to and are available for adoption by similar single or multiple institution research projects. CRediT authorship contribution statement Kimberly LeBlanc: Conceptualization, Writing – review & editing. Brian Hicks: Writing – review & editing, Funding acquisition, Conceptualization. Leo P. Sugrue: Writing – review & editing, Conceptualization. Kevin M. Gray: Writing – review & editing, Funding acquisition, Conceptualization. Charles Heyser: Writing – review & editing, Conceptualization. John H. Evans: Writing – review & editing, Conceptualization. Dylan G. Gee: Writing – review & editing, Funding acquisition, Conceptualization. Arielle Baskin-Sommers: Writing – review & editing, Funding acquisition, Conceptualization. Susan Bookheimer: Writing – review & editing, Funding acquisition, Conceptualization. Sandra Brown: Conceptualization, Funding acquisition, Project administration, Writing – review & editing. Duncan Clark: Writing – review & editing, Writing – original draft, Funding acquisition, Conceptualization. Funding The ABCD Study® is supported by the National Institutes of Health and additional federal partners under award numbers U01DA041048, U01DA050989, U01DA051016, U01DA041022, U01DA051018, U01DA051037, U01DA050987, U01DA041174, U01DA041106, U01DA041117, U01DA041028, U01DA041134, U01DA050988, U01DA051039, U01DA041156, U01DA041025, U01DA041120, U01DA051038, U01DA041148, U01DA041093, U01DA041089, U24DA041123, U24DA041147. A full list of supporters is available at https://abcdstudy.org/federal-partners.html. A listing of participating sites and a complete listing of the study investigators can be found at https://abcdstudy.org/consortium_members/. This manuscript reflects the views of the authors and may not reflect the opinions or views of the NIH or ABCD consortium investigators. Additional funding: P50DA046346 (Clark). Kim H. LeBlanc was involved in the preparation, review, and approval of the manuscript, consistent with her role on the ABCD Federal Partners Group. The views and opinions expressed in this manuscript are those of the authors only and do not necessarily represent the views, official policy, or position of the U.S. Department of Health and Human Services or any of its affiliated institutions or agencies. Other ABCD Consortium investigators designed and implemented the study and/or provided data but did not necessarily participate in the analysis or writing of this report. Declaration of Competing Interest The authors report no conflicts of interest. Contributor Information Duncan B. Clark, Email: clarkdb@upmc.edu. Arielle Baskin-Sommers, Email: arielle.baskin-sommers@yale.edu. Susan Bookheimer, Email: sbook@ucla.edu. Sandra Brown, Email: sandrabrown@ucsd.edu. John H. Evans, Email: jhevans@ucsd.edu. Dylan G. Gee, Email: dylan.gee@yale.edu. Kevin M. Gray, Email: graykm@musc.edu. Charles Heyser, Email: cheyser@ucsd.edu. Kim LeBlanc, Email: kimberly.leblanc@nih.gov. Leo P. Sugrue, Email: leo.sugrue@ucsf.edu. References